These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 24525422

  • 1. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
    Machado-Filho JA, Correia AO, Montenegro AB, Nobre ME, Cerqueira GS, Neves KR, Naffah-Mazzacoratti Mda G, Cavalheiro EA, de Castro Brito GA, de Barros Viana GS.
    Behav Brain Res; 2014 May 01; 264():116-25. PubMed ID: 24525422
    [Abstract] [Full Text] [Related]

  • 2. CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats.
    Aguiar LM, Macêdo DS, Vasconcelos SM, Oliveira AA, de Sousa FC, Viana GS.
    Brain Res; 2008 Jan 29; 1191():192-9. PubMed ID: 18164694
    [Abstract] [Full Text] [Related]

  • 3. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
    Yuan H, Sarre S, Ebinger G, Michotte Y.
    Brain Res; 2004 Nov 05; 1026(1):95-107. PubMed ID: 15476701
    [Abstract] [Full Text] [Related]

  • 4. Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats.
    Aguiar LM, Nobre HV, Macêdo DS, Oliveira AA, Freitas RM, Vasconcelos SM, Cunha GM, Sousa FC, Viana GS.
    Pharmacol Biochem Behav; 2006 Jul 05; 84(3):415-9. PubMed ID: 16844208
    [Abstract] [Full Text] [Related]

  • 5. L-linalool exerts a neuroprotective action on hemiparkinsonian rats.
    de Lucena JD, Gadelha-Filho CVJ, da Costa RO, de Araújo DP, Lima FAV, Neves KRT, de Barros Viana GS.
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Jun 05; 393(6):1077-1088. PubMed ID: 31938809
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
    Sarukhani M, Haghdoost-Yazdi H, Sarbazi Golezari A, Babayan-Tazehkand A, Dargahi T, Rastgoo N.
    Neurol Res; 2018 Jul 05; 40(7):523-531. PubMed ID: 29726751
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    Yuan H, Sarre S, Ebinger G, Michotte Y.
    J Neurosci Methods; 2005 May 15; 144(1):35-45. PubMed ID: 15848237
    [Abstract] [Full Text] [Related]

  • 9. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y, Agrawal AK.
    Neurobiol Dis; 2006 May 15; 22(2):421-34. PubMed ID: 16480889
    [Abstract] [Full Text] [Related]

  • 10. Histaminergic activity in a rodent model of Parkinson's disease.
    Nowak P, Noras L, Jochem J, Szkilnik R, Brus H, Körossy E, Drab J, Kostrzewa RM, Brus R.
    Neurotox Res; 2009 Apr 15; 15(3):246-51. PubMed ID: 19384597
    [Abstract] [Full Text] [Related]

  • 11. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.
    Ahmad M, Saleem S, Ahmad AS, Yousuf S, Ansari MA, Khan MB, Ishrat T, Chaturvedi RK, Agrawal AK, Islam F.
    J Neurochem; 2005 Apr 15; 93(1):94-104. PubMed ID: 15773909
    [Abstract] [Full Text] [Related]

  • 12. The preferential nNOS inhibitor 7-nitroindazole and the non-selective one N(G)-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats.
    Czarnecka A, Konieczny J, Lenda T, Lorenc-Koci E.
    Brain Res; 2015 Nov 02; 1625():218-37. PubMed ID: 26319690
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
    Ganser C, Papazoglou A, Just L, Nikkhah G.
    Exp Cell Res; 2010 Mar 10; 316(5):737-46. PubMed ID: 20060824
    [Abstract] [Full Text] [Related]

  • 16. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM, Faull RL, Connor B.
    Neuroscience; 2008 Feb 19; 151(4):1142-53. PubMed ID: 18201835
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP, Bennett RD, Zbarsky V, Ke B, Liang YF, Higa T, Bahorun T, Aruoma OI, Dexter DT.
    J Pharm Pharmacol; 2004 May 19; 56(5):649-54. PubMed ID: 15142343
    [Abstract] [Full Text] [Related]

  • 20. Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity.
    Sharma S, Taliyan R, Singh S.
    Behav Brain Res; 2015 Sep 15; 291():306-314. PubMed ID: 26048426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.